Acetazolamide for Monge's Disease: Efficiency and Tolerance of 6-Month Treatment
Acetazolamide for Monge's Disease: Efficiency and Tolerance of 6-Month Treatment
About this item
Full title
Author / Creator
Publisher
New York, NY: Am Thoracic Soc
Journal title
Language
English
Formats
Publication information
Publisher
New York, NY: Am Thoracic Soc
Subjects
More information
Scope and Contents
Contents
Monge's disease is characterized by an excessive erythrocytosis, frequently associated with pulmonary hypertension, in high-altitude dwellers. It has a considerable impact on public health in high-altitude regions. A preliminary study demonstrated the efficiency of acetazolamide (Acz) (250 mg/d for 3 wk) in reducing serum erythropoietin and hematoc...
Alternative Titles
Full title
Acetazolamide for Monge's Disease: Efficiency and Tolerance of 6-Month Treatment
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_199639321
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_199639321
Other Identifiers
ISSN
1073-449X
E-ISSN
1535-4970
DOI
10.1164/rccm.200802-196OC
